AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01527149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO
Study NCT01527149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT01527149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01527149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT01527149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV
Study NCT01527149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03350997 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trial 2 Exercise
Description: During the exercise session, subjects will exercise at 65% of VO2peak. One hour after the exercise session, participants will eat a standardized dinner which will NOT include the energy expended from their exercise session (- 350 kcal).
Study NCT03350997 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trial 1 Exercise
Description: During the exercise session, subjects will use a mouthpiece and nose clip (which will allow all of their expired air to pass through the metabolic cart for analysis of oxygen consumption and carbon dioxide production) for \~5 min at the beginning, middle and toward the end of exercise to verify they are exercising at 65% of VO2peak. This will allow us to accurately measure energy expenditure (kcal) during exercise. One hour after the exercise session, participants will eat a standardized dinner which includes the energy expended from their exercise session (+ 350 kcal).
Study NCT02610296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QPI-1002
Description: IV injection
Study NCT02610296 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: isotonic saline
Study NCT02096445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robot-assisted neurocognitive therapy of hand function
Description: 2 degrees-of-freedom hand rehabilitation robot to train fine motor skills during grasping and forearm rotation.
Study NCT02096445 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional neurocognitive rehabilitation
Description: Use sensory perception (tactile, proprioception but not vision!) to solve a by the therapist guided (passive) or patient controlled (active) therapy task, e.g. discrimination/identification of different spring resistances, sponges, different sized blocks, etc.
Study NCT02749396 — intervention group
Intervention type: DRUG
Intervention: Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Study NCT02749396 — intervention group
Intervention type: DRUG
Intervention: Extavia (interferon beta-1b), Novartis Pharma AG
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Study NCT02749396 — intervention group
Intervention type: DRUG
Intervention: Rebif (interferon beta-1a), Merck Serono Europe Ltd
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Study NCT02749396 — intervention group
Intervention type: DRUG
Intervention: Plegridy (peginterferon beta-1a), Biogen Idec Ltd
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Study NCT02749396 — intervention group
Intervention type: DRUG
Intervention: Avonex (interferon beta-1a), Biogen Idec Ltd
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Study NCT02749396 — intervention group
Intervention type: DRUG
Intervention: MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Study NCT01765166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SSGRIN-Parent Guide
Description: All children will receive traditional SSGRIN(Social Skills Group Intervention), but parents will vary in the level of parent treatment. Families will be randomly assigned to one of four treatment conditions(approximately 25% each): (a) Traditional SSGRIN child treatment with no parent involvement (ChO), (b) SSGRIN child treatment plus parent attention control (PAC), (c) SSGRIN child treatment plus Parent Guide-Home-study treatment (PG-HS), or (d) SSGRIN child treatment plus traditional Parent Guide treatment (PG).
Study NCT02749396 — intervention group
Intervention type: OTHER
Intervention: No MSDMDs therapy (control)
Description: Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
Study NCT01277016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMDex
Description: BMDex:~cycles 1 and 2 = MDex with bortezomib (B) at 1.3 mg/m2 i.v. on days 1, 4, 8 and 11 of a 28 day cycle, cycles 3 - 8 = MDex with bortezomib at 1.3 mg/m2 i.v. on days 1, 8, 15 and 22 of a 35 day cycle.
Study NCT04078841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ReaLife+ (RLP)
Description: RLP is a dietary supplement containing Acetogenins, vitamin, mineral and amino acids.
Study NCT04078841 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inert Brown powder
Description: Brown powder Inert brown powder to look similar to RLP
Study NCT00521950 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TPMT genotyping; Drug: azathioprine or 6-mercaptopurine
Description: Assessment of the polymorphisms G238C, G460A, and A719G in a venous blood sample to identify functional genetic variants (TPMT\*2, \*3A, \*3C) of the TPMT gene (chromosome 6) associated with reduced or negligible TPMT enzyme activity.~Patients are advised an initial treatment dose based on the enzyme activity:~* Normal: AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);~* Reduced: AZA 1-1.25 mg/kg/day or 6-MP 0.5-0.75 mg/kg/day;~* Negligible: AZA 0-0.2 mg/kg/day or 6-MP 0-0.1 mg/kg/day;
Study NCT00521950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azathioprine (AZA) or 6-mercaptopurine (6-MP)
Description: Patients will be advised a standard initial treatment dose:~* AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);
Study NCT01781936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide
Study NCT04196686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR/AR
Description: VR/AR headset with either passive or active content such as playing a game or watching a movie
Study NCT04196686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice Bath
Description: Participants immerse hand in ice bath and starting again with their original assigned group and keep hand submerged as long as they can withstand the cold or until 4 minutes have elapsed, whichever comes first. Participants will not be told of the specifics of the time limit, to avoid competitiveness and expectations and will be asked for pain scores every 30 seconds.
Study NCT02135861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCE-MRI scans
Description: Subjects will be placed supine in the scanner and will be prepared for intravenous contrast agent administration. The contrast agent is administered using a power injector before imaging.
Study NCT02135861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Gadobutrol at a dose less than or equal to 0.1 millimoles per kilogram (mmol/kg) will be given intravenously as a bolus using a power injector.
Study NCT03670823 — intervention group
Intervention type: DEVICE
Intervention: SIEMENS PRISMA MRI
Description: Collect data on brain activation from different methods
Study NCT03821896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversation Cards for Adolescents and Goal-Setting
Description: The intervention includes using an adolescent-tailored tool (a deck of cards) created by researchers at the University of Alberta and adolescents with obesity seeking weight management care. It contains a list of factors that make it easy or hard for teens to make and maintain healthy lifestyle changes. Its use will be paired with a S.M.A.R.T. goal-setting activity using principles of shared decision-making.
Study NCT03821896 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal-Setting
Description: Collaborative setting of S.M.A.R.T. goals using principles of shared decision-making.
Study NCT04514887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mild intraoperative hyperventilation
Description: Intraoperative mechanical ventilation of patients was adjusted so that end-tidal CO2 readings lie between 30-32 mmHg
Study NCT03379818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shape training intervention
Description: This intervention is based on on a study conducted by Smith and colleagues (2002), where they found that teaching typically developing infants to attend to shape by the end of the second year of life significantly enhances their word learning. Participants will be taught that the significant property they should focus in when learning and extending novel labels is shape. This will be done through play-like sessions.
Study NCT03379818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specific word training
Description: In this intervention, participants will be taught the names of 28 real objects. The target words have been selected from the Wordbank database, which is an open database that lists the proportion of children that know a specific word at a specific age. Twenty-eight words that are understood by 80% of the total child population at 25 months were randomly selected as target words. Techniques such as focused stimulation and modelling target words, which have proved to be useful for word learning, will be used.
Study NCT03606434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic exposure
Description: 30 minutes of intermittent hypoxia
Study NCT01873066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop system
Description: The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.
Study NCT01873066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real-time CGM
Description: Subject's glucose level is controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
Study NCT01873066 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real-time CGM
Description: Subject's glucose level is controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
Study NCT00560066 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell-derived influenza vaccine
Description: 1 dose of 0.5 mL in the deltoid region of the non-dominant arm
Study NCT00560066 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Egg-derived influenza vaccine
Description: 1 dose of 0.5 mL in the deltoid region of the non-dominant arm
Study NCT01945060 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: heart rate Control to Range System (hrCTR) using DiAs Platform
Description: Diabetes Assistant (DiAs) Medical Platform System~* A smart-phone medical platform (DiAs);~* Continuous Glucose Monitor;~* Insulin pump;~* Bluetooth connection;~* Remote Monitoring Server.
Study NCT01945060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heart rate Control to Range System (hrCTR) using DiAs Platform
Description: Diabetes Assistant (DiAs) Medical Platform System~* A smart-phone medical platform (DiAs);~* Continuous Glucose Monitor;~* Insulin pump;~* Bluetooth connection;~* Remote Monitoring Server.
Study NCT01945060 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DiAs Control-to-Range System not informed for heart rate
Description: Not informing system of heart rate during exercise.
Study NCT05923671 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Histological analysis
Description: Histological staining of gingival biopsies with haematoxylin-eosin.
Study NCT05923671 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemical analysis
Description: Immunohistochemical staining of gingival biopsies using anti-Vimentin, anti-Collagen I, anti-Collagen V, anti-Elastin, anti-Hyaluronic acid, anti-Smooth muscle actin, anti-Cluster of Differentiation 68 and anti-ki67 antibodies.
Study NCT05915650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: Carry out pain neuroscience education intervention for TKA patients
Study NCT05915650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine Education
Description: Carry out routine education intervention for TKA patients
Study NCT00972205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel 135 mg/m\^2 intravenously on day 6 over 180 minutes. Cycles are repeated every 21 days.
Study NCT00972205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-1(Registered Trademark)
Description: CBT-1 500 mg/m\^2 oral dose daily for 7 days in divided doses 3 times a day. Cycle days 1-7, repeated every 21 days. no antacids, H2 blocker, or gastric acid inhibiting agents will be administered within 4 hours before or after each daily dose.
Study NCT00972205 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tc 99m sestamibi
Description: 20 mCI baseline scan day 0; 20 mCI scan on 6th day of CBT-1 administered.
Study NCT03573648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelumab
Description: Avelumab (10 mg/kg) will be given intravenously on cycles 2 - 4, every 2 weeks.
Study NCT03573648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy
Description: The endocrine therapy given will depend on menopausal status.~Premenopausal women will receive tamoxifen AND either Goserelin or Leuprolide:~* Tamoxifen (20mg) will be given orally daily x 4 cycles. (Other Names: Nolvadex)~* Goserelin (3.6mg) will be given subcutaneously (under the skin) on Day 1 of each cycle x 4 cycles. (Other Names: Zoladex)~* Leuprolide (3.75mg) will be given intramuscularly (in the buttock, thigh, or upper arm) on Day 1 of each cycle x 4 cycles. (Other Names: Leuprorelin, Lupron, Eligard)~Postmenopausal women will receive letrozole:~- Letrozole (2.5mg) will be given orally daily each cycle x 4 cycles. (Other Names: Femara)
Study NCT03573648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Palbociclib (125 mg) will be given orally on days 1-21 of each cycle x 4 cycles.
Study NCT00966186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insertion fo ProSeal laryngeal mask airway
Description: Insertion fo ProSeal laryngeal mask airway using each of Standard technique or Rotational technique
Study NCT00966186 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion fo ProSeal laryngeal mask airway
Description: Insertion fo ProSeal laryngeal mask airway using each of Standard technique or Rotational technique
Study NCT04139330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-06
Description: Infuse NPC-06 intravenously
Study NCT04139330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NPC-06
Description: Infuse NPC-06 intravenously
Study NCT01264341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 10mg/kg intravenous every 2 weeks until disease progression, unacceptable toxicity or consent withdrawal.
Study NCT01264341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus 25mg intravenous once weekly until disease progression, unacceptable toxicity or consent withdrawal.
Study NCT01099696 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. infantis 35624
Description: B. infantis 35624 in white capsules
Study NCT01099696 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: white placebo capsules
Study NCT01762696 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MET
Description: Motivational Enhancement Therapy only
Study NCT01762696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MET
Description: Motivational Enhancement Therapy only
Study NCT01762696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOMENT
Description: The full MOMENT intervention: Motivational Enhancement Therapy + momentary and daily mobile self-monitoring + motivational feedback messages prompting participants to consider their individualized coping strategies to avoid using marijuana
Study NCT01885429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Positive Control
Description: Subject consumes 25g of whey protein following unilateral exercise
Study NCT01885429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Negative Control
Description: Subject consumes 6.25g of whey protein following unilateral exercise
Study NCT01885429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Protein Low Leucine Spike
Description: Subject consumes 6.25g of whey protein plus 3g of leucine following unilateral exercise
Study NCT01885429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Protein High Leucine Spike
Description: Subject consumes 6.25g of whey protein plus 5g of leucine following unilateral exercise
Study NCT01885429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Protein + High Leucine + BCAA Spike
Description: Subject consumes 6.25g of whey protein plus 5g of leucine plus valine and isoleucine (BCAA) following unilateral exercise
Study NCT02640274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led counselling programme
Description: The intervention is an individual nurse-led counselling programme in addition to usual care. The intervention includes 3 outpatient clinic visits (at weeks 2, 14 and 26) and two telephone calls (at weeks 4 and 16) by a cardiovascular nurse during the first 6 months early discharged. The counselling focuses on cardiac risk reduction behaviour based on guidelines issued by European Society of Cardiology and self-management support.
Study NCT02640274 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Study NCT02640274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Study NCT03954639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL 13.3Mg/mL Suspension for Injection
Description: Combined Sciatic and Adductor Canal Nerve Block with EXPAREL mixed with Bupivacaine (Single Dose)
Study NCT03954639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Combined Sciatic and Adductor Canal Nerve Block with Bupivacaine HCL
Study NCT02388243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention in Public Clinic
Description: The ASSIST-linked brief intervention includes a discussion, between the clinician and patient, of problem drinking and its associated adverse effects and how to address risky level of alcohol use, using motivational interviewing techniques, assess and manage any complication or co-morbidity uncovered, and request to the patient to follow-up in one month. Clinicians will also be asked to record their baseline and follow-up clinical assessment and management through clinical follow-up forms. The total brief intervention should be around 15 minutes, with a follow-up visit of about the same length a month later. This intervention in happening in a public clinic.
Study NCT02388243 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening Results in Public Clinic
Description: At each public clinic, a community health worker will ask patients presenting for consultation who are aged 18 years or older to be screened for healthy lifestyle and to receive feedback on their results. The screening will include self-reported weight and height, (for BMI calculation), level of physical activity, and the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The inclusion of the BMI and level of physical activity is to mask the purpose of the intervention, by decreasing the focus on substance use. The community health worker will provide the results of the BMI, physical activity and the ASSIST and will offer a leaflet with further explanation about how to address problems with those lifestyles
Study NCT00790803 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pegaptanib
Description: Five patients will receive intravitreous injections of Macugen 0.3 mg every 6 weeks as needed for a total of no more than five.
Study NCT02157818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Study NCT02157818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT04244448 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: receive dissolved form of BIKTARVY®
Description: The healthy volunteers will receive dissolved form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
Study NCT04244448 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: receive crushed form of BIKTARVY®
Description: The healthy volunteers will receive crushed form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).